Literature DB >> 6243340

Persistent Theiler's murine encephalomyelitis virus infection in mice depends on plaque size.

H L Lipton.   

Abstract

Theiler's murine encephalomyelitis virus (TMEV) is an enteric pathogen of mice which causes acute and chronic neurological disorders in the natural host. When brain-derived stocks of TMEV isolates are adapted to cell culture they predominantly form either large or small plaques. In this study the type of central nervous system (CNS) infection (acute versus chronic) and the associated disease occurring in mice inoculated intracerebrally with large and small plaque strains of TMEV was investigated. Large and small plaque strains of TMEV were found to vary in virulence, type of neurological disease produced and ability to establish persistent CNS infection in mice. Two large plaque strains, GDVII and FA viruses, were highly virulent, produced acute encephalitis, but were cleared from the nervous systems of surviving animals. Therefore, it appears that these large plaque variants do not cause persistent CNS infection in mice. In contrast, five small plaque strains, DA, WW, TO4, Yale and BeAn8386 viruses, were relatively avirulent, usually produced no illness during the first month after inoculation, but readily established persistent CNS infection in mice. Persistently infected mice later developed demyelinating disease. Having identified strains of TMEV that differ regarding their ability to persist, we now hope to be able to exploit this difference in elucidating the basic mechanism(s) of TMEV persistence.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243340     DOI: 10.1099/0022-1317-46-1-169

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  68 in total

1.  The GDVII strain of Theiler's virus spreads via axonal transport.

Authors:  C Martinat; N Jarousse; M C Prévost; M Brahic
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  L* protein of Theiler's murine encephalomyelitis virus is required for virus growth in a murine macrophage-like cell line.

Authors:  M Obuchi; J Yamamoto; T Odagiri; M N Uddin; H Iizuka; Y Ohara
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Sialylation of the host receptor may modulate entry of demyelinating persistent Theiler's virus.

Authors:  L Zhou; Y Luo; Y Wu; J Tsao; M Luo
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  The leader polypeptide of Theiler's murine encephalomyelitis virus is required for the assembly of virions in mouse L cells.

Authors:  C Badshah; M A Calenoff; K Rundell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  A single base deletion in the 5' noncoding region of Theiler's virus attenuates neurovirulence.

Authors:  A E Pritchard; M A Calenoff; S Simpson; K Jensen; H L Lipton
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Infection of macrophage primary cultures by persistent and nonpersistent strains of Theiler's virus: role of capsid and noncapsid viral determinants.

Authors:  Ignacio Mena; Jean-Pierre Roussarie; Michel Brahic
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Alternative translation initiation site in the DA strain of Theiler's murine encephalomyelitis virus.

Authors:  W P Kong; R P Roos
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

8.  The 5' noncoding sequences from a less virulent Theiler's virus dramatically attenuate GDVII neurovirulence.

Authors:  H L Lipton; M Calenoff; P Bandyopadhyay; S D Miller; M C Dal Canto; S Gerety; K Jensen
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

9.  Infectious cDNA clones of the DA strain of Theiler's murine encephalomyelitis virus.

Authors:  R P Roos; S Stein; Y Ohara; J L Fu; B L Semler
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  Axonal degeneration as a self-destructive defense mechanism against neurotropic virus infection.

Authors:  Ikuo Tsunoda
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.